Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: Value of augmented preparative regimens - A Southwest Oncology Group trial

Journal of Clinical Oncology

Volumn 16, Issue 1, 1998, Pages 48-55

  Stiff, Patrick J ^a   Dahlberg, Steve ^a   Forman, Stephen J ^a   McCall, Anne R ^a   Horning, Sandra J ^a   Nademanee, Auayporn P ^a   Blume, Karl G ^a   LeBlanc, Michael ^a   Fisher, Richard I ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; LACTATE DEHYDROGENASE;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLEEDING; CANCER RECURRENCE; CANCER RESISTANCE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LUNG ALVEOLITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; SURVIVAL; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 0031962299     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.1.48     Document Type: Article

References (34)

1. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard generation combination (CHOP) with three intensive chemotheraphy regimens for advanced Non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
2. Cabanillas F, Velasquez WS, McLaughlin P, et al: Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease. Semin Hematol 25:47-50, 1988 (suppl 2)
3. Velasquez WS, Cabanillas F, Salvador P, et al: Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ara-C and dexamethasone (DHAP). Blood 71:117-122, 1988
4. Kessinger A, Nademanee A, Forman SJ, et al: Autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. Hematol Oncol Clin North Amer 4:577-587, 1990
5. Philip T, Armitage JO, Spitzer G, et al: High dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgin's lymphoma. New Engl J Med 316:1493-1498, 1987
6. Petersen FB, Appelbaum FR, Hill R, et al: Autologous marrow transplantation for malignant lymphoma: A report of 101 cases from Seattle. J Clin Oncol 8:638-647, 1990
7. Vose JM, Armitage JO, Bierman PJ, et al: Salvage therapy for relapsed or refractory non-Hodgkin's lymphoma utilizing bone marrow transplantation. Am J Med 87:285-288, 1989
8. Freedman AS, Takvonan T, Anderson KC, et al: Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: Very low treatment-related mortality in 100 patients in sensetive relapse. J Clin Oncol 8:784-791, 1990
9. Phillips GL, Fay JW, Herzig RH, et al: The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy an autologous marrow transplantation. Blood 75:831-838, 1990
10. Gulati SC, Shank B, Black P, et al: Autologous bone marrow transplantation for patients with poor prognosis lymphoma. J Clin Oncol 6:1301-1313, 1988
11. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
12. Gulati S, Yanalom J, Acaba L, et al: Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation. J Clin Oncol 10:936-941, 1992
13. Blume KG, Forman SJ: High-dose etoposide (VP-16)-containing preparatory regimens in allogeneic and autologous bone marrow transplantation for hematologic malignancies. Semin Oncol 19:63-66, 1992 (suppl 13)
14. Horning SJ, Negnn RS, Chao NJ, et al: Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 12:2552-2558, 1994
15. Weaver CH, Petersen FB, Appelbaum FR, et al: High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. J Clin Oncol 12:2559-2566, 1994
16. Attal M, Canal P, Schlaifer D, et al: Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation. J Clin Oncol 12:141-148, 1994
17. Lazarus HM, Creger RJ, Diaz D: Simple method for the administration of high-dose etoposide during autologous bone marrow transplantation. Cancer Treat Rep 70:819-820, 1986
18. Kaplan EL, Meier P: Nonparametric estimations from incomplete observations. J Am Stat Assoc 53:457-481, 1958
19. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
20. Cox DR: Regression models and life tables. Stat Soc 34:187-202, 1972
21. Jagannath S, Dicke KA, Armitage JO, et al: High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Int Med 104:163-168, 1986
22. Zander AR, Culbert S, Jagannath S, et al: High dose cyclophosphamide, BCNU and VP-16 (CBV) as a conditioning regimen for allogeneic bone marrow for patients with acute leukemia. Cancer 59:1083-1086, 1987
23. Saez R, Dahlberg S, Appelbaum, et al: Autologous bone marrow transplantation in adults with non-Hodgkin's lymphoma: A Southwest Oncology Group study. Hematol Oncol 12:75-85, 1994
24. Santini G, Congiu A, Coser P, et al: High dose therapy with autologous bone marrow rescue (ABMT) in 100 aggressive poor-prognosis non-Hodgkin's lymphomas: A report of the non-Hodgkin's comparative study group. Proc Am Soc Clin Oncol 12:337, 1993 (abstr)
25. O'Dwyer PJ, Leyland JB, Alonso MT, et al: Etoposide (VP-12-312). Current status of an active anticancer drug. New Engl J Med 312:692-700, 1985
26. Chang TT, Gulati SC, Chou TC, et al: Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by computer analysis. Cancer Res 45:2434-2439, 1985
27. Dombemowsky P, Nissen NI: Combination chemotherapy and 4″dimethylepidophyllotoxin 9-(4,6-0-ethylidend-B-D glucopyranoside). VP16-213 (NS 141540) in L1210 leukemia. Eur J Cancer 12:181-188, 1976
28. Blume KG, Forman SJ, O'Donnell MR, et al: Total body irradiation and high dose etoposide: A new preparatory regimen for bone marrow transplantation in patients with advanced malignancies. Blood 69:1015-1020, 1987
29. Sladek NE, Doeden D, Powers JF, et al: Plasma concentrations of 4-hydrocyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat Rep 68:1247-1254, 1984
30. Skipper HE, Schnabel FM Jr, Mellet LB, et al: Implications of biochemical, cytokinetic, pharmacologic and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep 54:431-450, 1976
31. Schabel FM, Griswold DP, Laster WR, et al: Quantitative evaluation of anticancer agent activity in experimental animals. Pharmacol Ther 1:411-435, 1977
32. Oshimi K, Oshimi Y, Akutsu M, et al: Cytotoxicity of interleukin-2 activated lymphocytes for leukemia and lymphoma cells. Blood 68:938-948, 1986
33. Benyunes MC, Fefer A: Interleukin-2 in the treatment of hematologic malignancies, in Atkins MD, Mier JW (eds): Therapeutic Applications of IL-2. New York, NY, Dekker, 1993, pp 163-175
34. Fefer A, Benyunes MC, Massumoto C, et al: Interleukin-2 therapy after autologous bone marrow transplantation for hematological malignancies. Semin Oncol 20:41-45, 1993